1. New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application

3. Program Overview

4. Trastuzumab Improves DFS by 40%-50%

5. Trastuzumab Improves OS by 33%

6. Could We Give Less? The APT Trial

7. Study Design: APT Trial

8. APT Trial: 3-Year and 7-Year DFS Follow-Up

9. BCIRG-006: 10-Year Follow-Up Analysis

10. Disease-Free Survival (10.3 years)

11. Overall Survival (10.3 years)

12. HERA Trial Final Analysis (10-Year Follow-Up)

13. Standard Adjuvant Therapeutic Options in Early-Stage HER2-Positive Disease

14. APHINITY Trial

15. APHINITY Trial Design

16. Intent-to-Treat Primary Endpoint Analysis IDFS

17. APHINITY: IDFS Forest Plot by Subgroups

18. APHINITY Trial: Applying the Data to Clinical Practice

19. APHINITY Trial: Take-Home Messages

20. Could You Give More? Escalating Treatment in HER2-Positive EBC ExteNET Trial data

21. ExteNET Trial: Study Schema

22. ExteNET Trial Results: IDFS

23. ExteNET Trial Results: Subgroups

24. ExteNET Trial: Safety Data

25. ExteNET Trial: Conclusions

26. ExteNET Trial: Applying the Data to Clinical Practice

27. Concluding Remarks

28. Concluding Remarks, Cont’d

29. Abbreviations

30. Abbreviations (cont)